GlaxoSmithKline: Malaria, Falciparum trials

The registry lists 21 Malaria, Falciparum studies with GlaxoSmithKline as lead sponsor. 3 are open to participants now and 11 have results posted.

Phase 1 4Phase 2 7Phase 3 7Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsRecruitingNCT07646353Phase 1
• A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum MalariaRecruitingNCT07545681Phase 2
• A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 MonthsRecruitingNCT07036159Phase 2
• Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.CompletedNCT02699099Phase 3Results posted
• Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan AfricaCompletedNCT02251704Phase 4Results posted
• An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in AfricaCompletedNCT02207816Phase 3Results posted
• Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)CompletedNCT01345240Phase 3Results posted
• Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in ChildrenCompletedNCT01323972Phase 3Results posted
• Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African InfantsCompletedNCT01231503Phase 2Results posted
• Epidemiology Study of Malaria Transmission Intensity in AfricaCompletedNCT01190202Not applicableResults posted
• Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and ChildrenCompletedNCT01148459Phase 3Results posted
• Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI RegimenCompletedNCT00436007Phase 2Results posted
• Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian ChildrenCompletedNCT00360230Phase 2Results posted
• Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian InfantsCompletedNCT00289185Phase 2Results posted
• Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 YearsCompletedNCT07670377Phase 1
• A Study to Investigate the Safety of GSK4024484 in Healthy Adult ParticipantsCompletedNCT06171113Phase 1
• A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan AfricaCompletedNCT03855995
• A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607CompletedNCT02737007Phase 1
• Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated MalariaCompletedNCT00371735Phase 3
• Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated MalariaCompletedNCT00344006Phase 3
• Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese ChildrenCompletedNCT00307021Phase 2